Clinical trial · Observational
EpiCheck and Short-term Intensive Chemoresection in NMIBC
NCT04162704CI-TRIAL-00053206unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this explorative study is to evaluate whether EpiCheck can be used as a predictor of tumour response to short-term, intensive chemoresection with Mitomycin.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| EpiCheck | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- EpiCheck result
- timeFrame
- One to two months after short-term, intensive chemoresection
- description
- Number of patients with accordance between EpiCheck score and clinical findings at the time of evaluation cystoscopy
Secondary outcomes (3)
- measure
- EpiCheck result 2
- timeFrame
- One to two months after short-term, intensive chemoresection
- description
- Number of patients with discrepancy between EpiCheck score and clinical findings at the time of cystoscopy
- measure
- EpiCheck result 3
- timeFrame
- One to two months after short-term, intensive chemoresection
- description
- Trend of the EpiCheck test over time (increase/decrease/stable score) and its correlation to complete/incomplete tumour response
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with a known history of Ta HG with recurrent disease * Patients referred to short-term, intensive chemoresection * Patients older than 18 years Exclusion Criteria: * Known allergy or intolerance to Mitomycin * Incontinence or small bladder capacity (\< 100 mL) * Previous pelvic radiation therapy
References
Publications (0)
Data not yet available
No reference posted for this study.